Review
Oncology
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat, Daniele Generali
Summary: A meta-analysis on first-/second-line ET +/- TT for HR+/HER2-negative MBC showed that combination strategies were more effective than single-agent ET, with CDK4/6-inhibitors + ET being the most effective regimen. Single agent ET demonstrated comparable efficacy with ET+TT combinations in non-visceral and endocrine sensitive diseases, while mTORi-based combinations and PI3Ki + ET showed valid therapeutic options in endocrine-resistant and PIK3CA-mutant tumors. These results reinforce international treatment guidelines and can assist in therapeutic decision-making.
Article
Oncology
Jinhao Wang, Yaxin Liu, Yuehua Liang, Yue Zhang, Hang Dong, Tiantian Zheng, Jianjun Yu, Pan Du, Shidong Jia, Bonnie L. L. King, Jing Wang, Xiaoran Liu, Huiping Li
Summary: The determinants of outcome for younger vs. older patients with hormone receptor-positive/HER2-negative metastatic breast cancer were evaluated. The age of patients did not significantly affect the prognosis in this study. These findings support the development of biomarker-driven treatment strategies for these patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
Summary: This study showed that adding everolimus to letrozole with ovarian suppression can lead to longer progression-free survival in tamoxifen-exposed HR+, HER2- metastatic breast cancer patients, especially those with visceral metastasis.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
Summary: EVE + LET with ovarian suppression can prolong progression-free survival (PFS) in breast cancer patients with baseline visceral or bone metastases, and offer bone-protective effects in the overall study population. However, these clinical benefits did not translate into an overall survival (OS) benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Endocrinology & Metabolism
Shuhui You, Chengcheng Gong, Yi Li, Yizhao Xie, Yumeng Li, Yannan Zhao, Biyun Wang
Summary: In HoR-positive MBC, patients with low and zero HER2 expression have similar clinical characteristics and respond similarly to endocrine treatment, but the chemotherapy effect is worse in the HER2-low patients. Moreover, the transformation of HER2 status from primary to metastatic lesions may have potential influence on chemotherapy outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Layal Al Mahmasani, Ghid Amhaz, Reine Abou Zeidane, Nathalie Chamseddine, Taha Hatab, Saad Sabbagh, Maya Charafeddine, Hazem I. Assi
Summary: Metastatic breast cancer is a diverse disease, and the optimal treatment sequence for patients with HR-positive, HER2-negative MBC remains unknown. This study aimed to investigate oncologists' preferences in the choice and sequence of treatment for these patients. The study found a higher percentage of patients receiving chemotherapy as first-line treatment compared to the reported literature.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Francesco Schettini, Elia Segui, Benedetta Conte, Esther Sanfeliu, Blanca Gonzalez-Farre, Pedro Jares, Sergi Vidal-Sicart, Sergi Ganau, Isaac Cebrecos, Fara Braso-Maristany, Montserrat Munoz, Aleix Prat, Maria Vidal
Summary: This clinical case confirms the presence of non-luminal subtypes in HR+/HER2-neg disease and highlights the potential therapeutic implications in the metastatic setting. It also questions the recommendation of upfront chemotherapy in the case of a visceral crisis in the era of CDKi-based regimens. Further evaluation in prospective and larger studies is needed.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Benoite Mery, Coralie Poulard, Muriel Le Romancer, Olivier Tredan
Summary: The AKT protein kinase has a key role in breast cancer, particularly in hormone receptor-positive breast cancer, where hyperactivation of the PI3K/AKT signaling pathway leads to treatment resistance. AKT inhibitors and PI3K/mTOR inhibitors have been developed and approved for the treatment of this type of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Jie Chen, Jin Zhu, Shuai-Jun Xu, Jun Zhou, Xiao-Fei Ding, Yong Liang, Guang Chen, Hong-Sheng Lu
Summary: TM4SF1 is downregulated in HR(+)HER2(-) breast cancer, and its overexpression suppresses cell proliferation in this cancer subtype.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Quchang Ouyang, Ying Wang, Jian Zhang, Qiong Wu, Hongying Wei, Chuan Li, Xiaoling Qian, Xichun Hu
Summary: This study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of HS-10352, a selective PI3K alpha inhibitor, in patients with HR-positive, HER2-negative ABC. The results showed that HS-10352 at a dosage of 6 mg once-daily was well-tolerated and showed preliminary antitumor activity in patients with PIK3CA mutated tumors.
Article
Medicine, General & Internal
Ioannis A. Voutsadakis
Summary: This study investigates ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compares them with cancers of the same subtype and low mutation numbers. The results show that breast cancers with high mutation numbers have a higher prevalence of certain genetic mutations and DNA damage response genes. However, the prognosis of these breast cancers is not significantly different compared to those with lower mutation counts. These findings provide information on the suitability of these cancers for immunotherapy and potential combination therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Jun Yamamura, Shunji Kamigaki, Junya Fujita, Hiroki Osato, Hironobu Manabe, Yumiko Tanaka, Wataru Shinzaki, Yukihiko Hashimoto, Yoshifumi Komoike
Summary: For patients with recurrent metastatic HR+/HER2- breast cancer, having a single metastasis is associated with better prognosis compared to having multiple metastases. Single metastases with diffuse lesions are an independent risk factor for worse prognosis and progression to multiple metastases, while multiple metastases involving liver or brain metastasis are significant independent poor prognostic factors. Other multiple metastases not involving these organs are not significantly related to prognosis after recurrence.
Review
Oncology
Matthew R. Kearney, Julia E. McGuinness, Kevin Kalinsky
Summary: While checkpoint inhibitors have shown benefit in PDL1-positive triple negative breast cancer, their efficacy in hormone receptor-positive, HER2-negative breast cancer remains limited. Combining immunotherapy with other treatments such as chemotherapy, endocrine therapy, and targeted agents may enhance anti-tumor activity in this subtype.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Pharmacology & Pharmacy
Elizabeth Hageman, Mia E. Lussier
Summary: This article discusses the approval and efficacy of elacestrant in the treatment of hormone receptor positive (HR+) advanced breast cancer. It shows that elacestrant is a potentially effective alternative for patients with ESR1 mutations who have failed previous therapies. Elacestrant has a comparable safety profile to other endocrine therapies and can be used after traditional chemotherapy.
ANNALS OF PHARMACOTHERAPY
(2023)
Letter
Hematology
Somedeb Ball, Akriti G. Jain, Luis E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, Kendra L. Sweet, Jeffrey E. Lancet, David M. Swoboda, Eric Padron, Rami S. Komrokji, David A. Sallman
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Letter
Hematology
Amber C. King, Taylor M. Weis, Andriy Derkach, Somedeb Ball, Manu Pandey, Michael J. Mauro, Aaron D. Goldberg, Maximilian Stahl, Christopher Famulare, Martin S. Tallman, Eunice S. Wang, Andrew T. Kuykendall, Raajit K. Rampal
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Review
Oncology
Somedeb Ball, Rami S. Komrokji, David A. Sallman
Summary: Myelodysplastic syndromes (MDS) are clinically and molecularly heterogeneous, with precise risk stratification being crucial for optimal management strategies. Traditional prognostic scoring systems have limitations such as lack of dynamicity and inconsistent risk estimates. Incorporating genetic mutations into risk stratification could improve model performance according to recent studies.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D'Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertu, Marco Brociner, Andrew Kuykendall, Francesco Passamonti
Summary: Ruxolitinib is commonly used in the treatment of myelofibrosis, but many patients lose response over time. This study identified predictors of survival and developed a prognostic model to identify patients who may benefit from a treatment switch.
Article
Oncology
Anna R. Giuliano, Jeffrey E. Lancet, Shari Pilon-Thomas, Ning Dong, Akriti G. Jain, Elaine Tan, Somedeb Ball, Shelley S. Tworoger, Erin M. Siegel, Junmin Whiting, Qianxing Mo, Christopher L. Cubitt, Christopher W. Dukes, Jonathan A. Hensel, Robert J. Keenan, Patrick Hwu
Summary: This cohort study found that the mRNA-1273 SARS-CoV-2 vaccine induced variable antibody responses that differed by cancer diagnosis and treatment received. These findings suggest that patients with hematologic cancer and those who are receiving immunosuppressive treatments may need additional vaccination doses.
Review
Oncology
Juan Carlos Laguna, Tim Cooksley, Shin Ahn, Nikolaos Tsoukalas, Thein Hlaing Oo, Norman Brito-Dellan, Francis Esposito, Carmen Escalante, Carme Font
Summary: Central venous access devices (CVADs), such as central venous catheters and peripherally inserted central catheters (PICCs), are crucial in cancer treatment. However, catheter-related thrombosis (CRT) is a common non-infectious complication associated with their use. CRT can lead to treatment delays and potentially life-threatening complications. It is important to consider various risk factors and standardize catheter placement and maintenance to prevent CRT. Current recommendations for managing established CRT are based on anticoagulation therapy for lower limb venous thrombosis.
SUPPORTIVE CARE IN CANCER
(2022)
Meeting Abstract
Oncology
K. Z. Thein, T. Win Htut, Y. M. Myat, M. M. Han, T. H. Oo
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Somedeb Ball, Sanam Loghavi, Amer M. Zeidan
Summary: Pathogenic alterations of TP53 are a poor prognostic factor in MDS and AML. TP53 mutations drive resistance to chemotherapy. Novel treatment combinations improve response rates but not survival. Future research should focus on finding new therapies.
LEUKEMIA & LYMPHOMA
(2023)
Meeting Abstract
Hematology
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo
Meeting Abstract
Hematology
Felipe Soto-Lanza, Denai R. Milton, Thein H. Oo, Cristhiam Mauricio Rojas Hernandez
Meeting Abstract
Hematology
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo
Article
Oncology
Akriti G. Jain, Somedeb Ball, Luis E. Aguirre, Katherine A. Tobon, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David Sallman, Jeffrey E. Lancet, Kendra Sweet
Summary: This study is the first to report on the use of next-generation sequencing (NGS) at best response and before allogeneic stem cell transplant (alloSCT) in patients treated with CPX-351 for acute myeloid leukemia. The study found that overall survival (OS) and relapse-free survival (RFS) were numerically longer among patients who cleared mutations, but this did not reach statistical significance. Additionally, alloSCT improved RFS regardless of mutational clearance.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Kyaw Z. Thein, Amadeo B. Biter, Kimberly C. Banks, Andrew W. Duda, Jennifer Saam, Jason Roszik, Filip Janku, Ferdinandos Skoulidis, John V. Heymach, Scott Kopetz, Funda Meric-Bernstam, David S. Hong
Summary: This study conducted a comprehensive analysis of KRAS(G12C) mutations in different types of cancer through liquid biopsy. The results showed that KRAS(G12C) mutations were detected in various cancers, with the highest detection rate in lung cancer.
JCO PRECISION ONCOLOGY
(2022)
Meeting Abstract
Oncology
Yumeng Zhang, Chuanyi Lu, Endi Wang, Lynh Nguyen, Marietya Lauw, Somedeb Ball, Ning Dong, Lynn Moscinski, Onyee Chan, Seongseok Yun, David Sallman, Lubomir Sokol, Bijal Shah, Todd Knepper, Jeffrey Lancet, Rami Komrokji, Andrew Kuykendall, Eric Padron, Ling Zhang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Oncology
Benjamin Garmezy, Jinesh Gheeya, Heather Y. Lin, Yuefan Huang, Taebeom Kim, Xianli Jiang, Kyaw Z. Thein, Patrick G. Pilie, Fadl Zeineddine, Wanlin Wang, Kenna R. Shaw, Jordi Rodon, John Paul Shen, Ying Yuan, Funda Meric-Bernstam, Ken Chen, Timothy A. Yap
Summary: This study demonstrated that patients with pathogenic POLE mutations had better clinical outcomes and response to ICI therapy compared to those with benign variants, including improved clinical benefit rate, progression-free survival, overall survival, and longer treatment duration.
JCO PRECISION ONCOLOGY
(2022)